AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $90,791 | -1.3% | 1,795 | -8.9% | 0.06% | 0.0% |
Q2 2023 | $92,026 | +5.1% | 1,971 | -13.9% | 0.06% | +14.6% |
Q1 2023 | $87,577 | -49.5% | 2,289 | -27.7% | 0.05% | -47.3% |
Q4 2022 | $173,387 | -60.8% | 3,164 | -75.6% | 0.09% | -48.3% |
Q3 2022 | $442,000 | +262.3% | 12,981 | +0.8% | 0.18% | +291.1% |
Q2 2022 | $122,000 | +9.9% | 12,882 | +65.1% | 0.04% | -10.0% |
Q1 2022 | $111,000 | -36.6% | 7,802 | -5.6% | 0.05% | -24.2% |
Q4 2021 | $175,000 | +9.4% | 8,266 | +15.7% | 0.07% | -5.7% |
Q3 2021 | $160,000 | -14.4% | 7,146 | -5.0% | 0.07% | -9.1% |
Q2 2021 | $187,000 | -38.3% | 7,526 | -28.0% | 0.08% | -39.8% |
Q1 2021 | $303,000 | +14.3% | 10,454 | +1.7% | 0.13% | +16.4% |
Q4 2020 | $265,000 | -32.2% | 10,276 | -19.0% | 0.11% | -46.3% |
Q3 2020 | $391,000 | +8.9% | 12,686 | -12.1% | 0.20% | +20.6% |
Q2 2020 | $359,000 | -0.8% | 14,425 | -15.4% | 0.17% | +14.1% |
Q1 2020 | $362,000 | -16.4% | 17,057 | -12.7% | 0.15% | +109.9% |
Q4 2019 | $433,000 | – | 19,531 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |